samedan logo
 
 
 
spacer
home > ebr > summer 2004 > european life sciences
PUBLICATIONS
European Biopharmaceutical Review

European Life Sciences

As the biotech sector continues to mature, its leading companies will deliver more and more products thereby dramatically improving overall sentiment towards the sector. Despite the investor challenges experienced in recent years, over the past 12-18 months we have witnessed a significant and sustained upswing in the US and European markets, as well as in the biotechnology sector in general. On the whole, the prices of quoted companies in both the US and Europe significantly improved over the year to December 2003, with the NASDAQ Biotech Index up more than 50 per cent over the previous 12 months (1). However, since March 2004 there has been a slight correction in both US and European biotech stocks (as shown in Figure 1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Mark Clement, Chief Executive of Merlin Biosciences

Mark Clement is Chief Executive Officer at Merlin Biosciences. He joined Merlin in March 2000 and serves as Chief Executive. In 1997, he founded MCC Services, a corporate finance consultancy, where he led assignments from nine life sciences companies, including four Fund I investments. In 1992, he co-founded Celsis International plc (a specialist in microbial risk management), where he served as Group Finance Director with responsibility for both finance and European operations. Prior to this, he spent a year at WestLB Panmure as an Associate Director (Corporate Finance). Mark is a Fellow of the Institutes of Chartered Accountants in England and Wales, the Securities Institute and the Insolvency Practitioners Association.

spacer
Mark Clement
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera joins IPAC-RS as an Associate Member

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Nemera’s decision to join IPAC-RS is part of its commitment to advance science and innovation. Nemera is committed to enhancing better patient outcomes by seeking innovative solutions and contributing actively to discussions about the future of drug delivery devices. Its membership in IPAC-RS will facilitate this important commitment.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement